Sign in

Hans-Joachim Anders

@hjanders.bsky.social
301 followers 98 following 36 posts

Physician scientist from LMU Munich trying to understand how to maximise kidney lifespan for patients with kidney diseases

PostsRepliesMedia
Reposted by Hans-Joachim Anders
Mo. Elrggal @kidneyman.bsky.social · 20/12/2025
CKD prevalence in elderly and the eGFR inflation effect, a very important paper in the @ndt-era.bsky.social . Not just for elderly but also for the young CKD population academic.oup.com/ndt/article/... #nephinp #nephrology_in_practice
073
Reposted by Hans-Joachim Anders
Mo. Elrggal @kidneyman.bsky.social · 13/12/2025
A must read comprehensive article @ndt-era.bsky.social focusing on the biology/genetics of kidney stone. It highlights GWASs of calcium and phosphate handling (e.g., SLC34A1, CYP24A1, CaSR) and crystallization inhibitors (e.g., UMOD, pyrophosphate-related genes). academic.oup.com/ndt/article-...
043
Reposted by Hans-Joachim Anders
NEJM.org @nejm.org · 24/11/2025
In older patients with frailty who were receiving antihypertensive drugs and had a systolic blood pressure below 130 mm Hg, reducing antihypertensive drugs did not lead to lower all-cause mortality over 4 years than usual care. Full RETREAT-FRAIL trial results and Research Summary: nej.md/45NUK9v
The New England Journal of Medicine                   
Reduction of Antihypertensive Treatment in Nursing Home Residents 
A Research Summary based on Benetos A et al. | 10.1056/NEJMoa2508157 | Published on August 29, 2025 

Visual representations of the patients in the trial and the treatments they were assigned.    

Read the full Research Summary at NEJM.org.
0136
Reposted by Hans-Joachim Anders
Kidney International @kidneyint.bsky.social · 31/10/2025
Sodium glucose cotransporter 2 inhibition does not improve active lupus nephritis in MRLlpr/lpr mice doi.org/10.1016/j.kint.2025.09.026 #NephSky #MedSky #lupus #nupusnephritis #kidneydisease @vhir.bsky.social @lmumuenchen.bsky.social @hjanders.bsky.social @pepasolerr.bsky.social
052
Hans-Joachim Anders @hjanders.bsky.social · 30/10/2025
Now open access in @ndt-era.bsky.social Rationale, Design, and Baseline Characteristics of the TRANSCEND-CKD trial of Retatrutide in pts with CKD 🧐Retatrutide is a novel triple incretin agonist targeting GIP, GLP-1, and glucagon receptors ▶️ academic.oup.com/ndt/article/...
010
Hans-Joachim Anders @hjanders.bsky.social · 28/10/2025
Now open access in @ndt-era.bsky.social Autosomal Dominant Tubulointerstitial Kidney Disease (ADTKD) in Chinese Pts 🧐This Chinese ADTKD cohort reveals a high prevalence of UMOD and HNF1B variants ▶️ academic.oup.com/ndt/article-...
020
Hans-Joachim Anders @hjanders.bsky.social · 28/10/2025
Now online in @ndt-era.bsky.social Neutrophil infiltration of kidney grafts: incidence, associated factors and graft survival 🧐NTI should prompt the search for urinary tract infection and rejection ▶️ academic.oup.com/ndt/article-...
010
Reposted by Hans-Joachim Anders
Hans-Joachim Anders @hjanders.bsky.social · 30/09/2025
Now online in @ndt-era.bsky.social Recombinant alpha-1 microglobulin to improve outcomes in survivors of AKI 🧐RMC-035 may improve kidney outcomes in settings characterized by oxidative and ischemia-reperfusion injury. ▶️ academic.oup.com/ndt/article-...
032
Reposted by Hans-Joachim Anders
Jasmine Sethi @jasminenephro.bsky.social · 14/10/2025
🧬Complement Pathways and Regulators in Kidney Ds doi.org/10.1093/ndt/... @hjanders.bsky.social
051
Hans-Joachim Anders @hjanders.bsky.social · 08/10/2025
Now open access in @ndt-era.bsky.social How can we target the production of pathogenic IgA in IgAN? 🧐Drugs directed at mucosal B cells, inhibitors of APRIL and BAFF, and drugs that target IgA-producing plasma cells ▶️https://academic.oup.com/ndt/article/doi/10.1093/ndt/gfaf185/8262262
021
Hans-Joachim Anders @hjanders.bsky.social · 30/09/2025
Now online in @ndt-era.bsky.social Recombinant alpha-1 microglobulin to improve outcomes in survivors of AKI 🧐RMC-035 may improve kidney outcomes in settings characterized by oxidative and ischemia-reperfusion injury. ▶️ academic.oup.com/ndt/article-...
032
Hans-Joachim Anders @hjanders.bsky.social · 28/09/2025
Now open access in @ndt-era.bsky.social Prevalence of Strongyloides stercoralis in HD pts in Vienna 🧐Implementation of targeted screening for S. stercoralis should be considered in pre-KTX protocols in Europe. ▶️ academic.oup.com/ndt/article/...
021
Hans-Joachim Anders @hjanders.bsky.social · 27/09/2025
Now open access in @ndt-era.bsky.social QT-Prolonging Medications: Prevalence of Use and Associated Risks in CKD 🧐The pathophysiological relevance, prevalence, and CV consequences of QT-prolonging drug use in the CKD setting ▶️https://academic.oup.com/ndt/article/doi/10.1093/ndt/gfaf196/8263915
000
Hans-Joachim Anders @hjanders.bsky.social · 18/09/2025
Now open access in @NDTsocial Anti-GBM disease - Treatment Standard 🧐 Anti-GBM and ANCA positive pts have a higher relapse risk and require maintenance immunosuppressive treatment ▶️ academic.oup.com/ndt/article/...
143
Hans-Joachim Anders @hjanders.bsky.social · 16/09/2025
Now open access in @ndt-era.bsky.social Comparing CKD populations with T1D and T2D based on FINE-ONE and FIDELITY populations 🧐Similarities between populations may inform the translation of clinical evidence on finerenone from CKD and T2D to CKD and T1D. ▶️ academic.oup.com/ndt/article/...
000
Hans-Joachim Anders @hjanders.bsky.social · 14/09/2025
Now open access in @ndt-era.bsky.social al CKD of unexplained cause (CKDx): A consensus statement by the Genes &Kidney Working Group of the ERA 🧐Check also our 2 open access editorials on this innovative concept. ▶️ academic.oup.com/ndt/article/...
130
Hans-Joachim Anders @hjanders.bsky.social · 12/09/2025
Now online in @ndt-era.bsky.social Transition of pts with hereditary nephropathies from pediatric to adult care from WG Genes&Kidney of ERA and ESPN 🧐To improve health outcomes, pt empowerment, and engagement for young people with CKD. ▶️ academic.oup.com/ndt/article-...
031
Hans-Joachim Anders @hjanders.bsky.social · 12/09/2025
New RCT online in @ndt-era.bsky.social Additive Effects of Oral Calcitriol on pts with IgAN receiving RAS Blockade 🧐The addition of 0.25 μg/d calcitriol to RASi safely lowered residual proteinuria and slowed eGFR decline in pts with IgAN ▶️ academic.oup.com/ndt/article-...
110
Hans-Joachim Anders @hjanders.bsky.social · 08/09/2025
Now open access in @ndt-era.bsky.social Protein profiles and associated biological pathways among different etiologies of CKD: new insights from DAPA-CKD 🧐Distinct proteomic differences unravel the heterogeneous pathophysiology of human CKD. ▶️ academic.oup.com/ndt/article/...
000
Reposted by Hans-Joachim Anders
AIN/Sandipan Shringi @nephrosage.bsky.social · 05/09/2025
Which agent are you using in post kidney transplant dyslipidemia? statin, ezetimibe, PCSK9 modulators or bempedoic acid? More info: academic.oup.com/ndt/article/... @ndt-era.bsky.social, @hjanders.bsky.social
academic.oup.com
Lipid-lowering agents in solid organ transplant recipients
ABSTRACT. Although pre- and post-transplant dyslipidaemia is one of the most prevalent modifiable risk factors associated with an increased risk of major c
041
Reposted by Hans-Joachim Anders
AIN/Sandipan Shringi @nephrosage.bsky.social · 04/09/2025
Acute kidney injury, acute kidney disease and chronic kidney disease: challenges and research perspectives More info: academic.oup.com/ndt/article/... @ndt-era.bsky.social, @hjanders.bsky.social
051
Reposted by Hans-Joachim Anders
AIN/Sandipan Shringi @nephrosage.bsky.social · 03/09/2025
A step toward personalized medicine More info: academic.oup.com/ndt/article/... @ndt-era.bsky.social, @hjanders.bsky.social, @Richard Glassock, @Andrew Rule, @Aleksandar Denic, @delanaye.bsky.social
021
Hans-Joachim Anders @hjanders.bsky.social · 16/08/2025
Now online in @ndt-era.bsky.social Cost-effectiveness of protein restricted diets in advanced CKD 🧐In pts adherent to diet prescription, low-protein diets delay the start of dialysis, improve survival, and save money ▶️ academic.oup.com/ndt/article-...
academic.oup.com
Cost-effectiveness of protein restricted diets in advanced CKD
AbstractBackground. The dialysis costs are not sustainable everywhere, resulting in many avoidable deaths. Interventions that postpone the start of dialysi
040
Hans-Joachim Anders @hjanders.bsky.social · 16/08/2025
Now open access in @ndt-era.bsky.social Anti-nephrin, anti-podocin and anti-Kirrel1 antibodies: Biological challenges and clinical implications 🧐 Clinical implementation of anti-slit diaphragm antibody testing = precision dx and tx in podocytopathies ▶️ academic.oup.com/ndt/article/...
0188
Hans-Joachim Anders @hjanders.bsky.social · 13/08/2025
Now open access in @ndt-era.bsky.social What do RCTs teach us about the pathophysiology of human IgAN? 🧐B cells/PC produce the IgAN antigen GdIgA1 as well as the respective autoantibodies, hence targeting B cells/PC will be most clever. ▶️ academic.oup.com/ndt/article/...
041
Hans-Joachim Anders @hjanders.bsky.social · 12/08/2025
Now online in @ndt-era.bsky.social Perlecan is a novel target of autoantibodies in anti-glomerular basement membrane disease 🧐Triple-positive pts (anti-type IV collagen, -laminin 521, and -perlecan) = highest prevalence of lung hemorrhage and ESKD ▶️ academic.oup.com/ndt/article-...
022
Hans-Joachim Anders @hjanders.bsky.social · 11/08/2025
Now open access in @ndt-era.bsky.social Evolving strategies for early diagnosis, proactive prevention and treatment of CKD 🧐"Inferior doctors provide KRT Mediocre doctors treat CKD Superior doctors prevent kidney disease" ▶️ academic.oup.com/ndt/article/...
010
Reposted by Hans-Joachim Anders
Mo. Elrggal @kidneyman.bsky.social · 14/07/2025
Read this piece from the ERAKI working group at the @ndt-era.bsky.social regarding the results of the DEFENDER trial published last August @jama.com academic.oup.com/ndt/article/...
021
Hans-Joachim Anders @hjanders.bsky.social · 13/07/2025
Now online in @ndt-era.bsky.social Acute post-streptococcal GN (in children) - treatment standard 🧐 Pathophysiology, diagnosis, outcome prediction, and management standard ▶️ academic.oup.com/ndt/article-...
020
Hans-Joachim Anders @hjanders.bsky.social · 12/07/2025
Now online in @ndt-era.bsky.social Multifactorial chronic kidney disease 🧐 Life is long and our kidneys have to take many hits, hence, adult CKD is usually multifactorial as is atherosclerosis or dementia. RF control is key and RF vary across world regions ▶️ academic.oup.com/ndt/article-...
020
Hans-Joachim Anders @hjanders.bsky.social · 12/07/2025
Now online in @ndt-era.bsky.social Treatment standard: CKD in the geriatric patient 🧐Pat.-centered communication about preferences and prioritized Tx goals sonsiders psychosocial factors and home environment, as well as their medical needs and prognosis ▶️ academic.oup.com/ndt/article-...
020
Reposted by Hans-Joachim Anders
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 07/07/2025
Following on CONFIDENCE (on #NephJC tomorrow) The design and baseline data from MIRO-CKD trial academic.oup.com/ndt/advance-... N = 614, balcinerone, dapagliflozin Urine ACR outcome #NephSky
073
Reposted by Hans-Joachim Anders
Nephrology Journal Club @nephjc.bsky.social · 25/06/2025
T0d: #NephJC CKD’s story is shifting- RASi, flozins, MRAs, and GLP-1s have redrawn the map, turning a therapeutic desert into a landscape of cardio-renal possibility Relevant infographic from @brendonneuen.bsky.social‬ academic.oup.com/ndt...
2157
Reposted by Hans-Joachim Anders
Nephrology Journal Club @nephjc.bsky.social · 25/06/2025
T0f: #NephJC CKD’s a mess—multisystemic, unpredictable, and stuck in primary care. We’ve got the evidence, the drugs, the guidelines. What don’t we have? Follow-through. Evidence doesn’t treat patients. Do people do good or bad?
3122
Hans-Joachim Anders @hjanders.bsky.social · 18/06/2025
The new Impact factors are out. Here is a list of some kidney journals @ndt-era.bsky.social
020
Hans-Joachim Anders @hjanders.bsky.social · 17/06/2025
Ongoing discussion about UACR or UPCR in GN captured in @ndt-era.bsky.social The use of UACR or UPCR for risk prediction in IgAN url:https://academic.oup.com/ndt/article-abstract/40/1/1/7702452 UACR predicts kidney events in IgAN url:https://academic.oup.com/ndt/article/40/3/465/7660570
132
Hans-Joachim Anders @hjanders.bsky.social · 05/06/2025
Now first late breaker clinical trial session at #ERA2025
010
Hans-Joachim Anders @hjanders.bsky.social · 03/06/2025
Now open access in @ndt-era.bsky.social Antibody-mediated Rejection - Treatment Standard 🧐Ongoing phase 2 trials offer hope for effective, therapies targeting different aspects of AMR. academic.oup.com/ndt/article/...
010
Hans-Joachim Anders @hjanders.bsky.social · 02/06/2025
Now open access in the June edition of @ndt-era.bsky.social Disease-modifying anti-nephropathic drugs (DMANDs)—a definition proposed by the IWG of ERA 🧐Not all drugs that reduce UPCR may be disease-modifying. SGLT2i are a DMAND only for GN-related CKD. academic.oup.com/ndt/article/...
010
Reposted by Hans-Joachim Anders
NDT @ndt-era.bsky.social · 26/05/2025
🤩Call for NDT Cover Images! If you have an eye-catching image focused on kidney disease, please email it to ndt@era-online.org More info👇 academic.oup.com/ndt/pages/ca... 🤩The accepted images will be featured in the NDT Art Gallery and selected images will also appear on future covers
academic.oup.com
Call for NDT Cover Images
A picture is worth a thousand words!  NDT is excited to announce a call for the cover images for our future issues of the Journal. If you have an ey
046
Reposted by Hans-Joachim Anders
NDT @ndt-era.bsky.social · 21/05/2025
Effect of pharmacist interventions in chronic kidney disease: a meta-analysis doi.org/10.1093/ndt/...
031
Reposted by Hans-Joachim Anders
NDT @ndt-era.bsky.social · 20/05/2025
Genotype-Phenotype Correlations and Clinical Outcomes of Genetic TRPC6 Podocytopathies doi.org/10.1093/ndt/... This study shows unique clinical and genetic correlations of TRPC6-AP, which may enable personalised care and promising novel therapies
041
Hans-Joachim Anders @hjanders.bsky.social · 21/05/2025
Now open access in @NDT-era.bsky.social Individualizing renoprotective therapy in obese pts with CKD 👍Multitarget therapy incl. RASi, SGLT2i, GLP-1ra and nsMRAs improve MACE and MAKE in pts with overweight/obesity and T2DM ▶️https://academic.oup.com/ndt/article/doi/10.1093/ndt/gfaf069/8129710
000
Reposted by Hans-Joachim Anders
NDT @ndt-era.bsky.social · 05/05/2025
A novel system to continuously estimate intradialytic blood pressure in real time doi.org/10.1093/ndt/...
031
Reposted by Hans-Joachim Anders
NDT @ndt-era.bsky.social · 29/04/2025
🤩Check out the new May issue of NDT! academic.oup.com/ndt/issue
022
Reposted by Hans-Joachim Anders
NDT @ndt-era.bsky.social · 28/04/2025
Cardiovascular involvement in ANCA-associated vasculitis doi.org/10.1093/ndt/...
022
Reposted by Hans-Joachim Anders
Nature Reviews Nephrology @natrevneph.nature.com · 25/04/2025
An editorial in Nature calls on Member States to support a resolution that calls for the WHO to recognize kidney disease as a major cause of death and disability go.nature.com/3YQfISu
go.nature.com
Kidney disease is a worldwide killer. Treat it that way
The international community has a golden opportunity to start reining in the escalating, mostly ignored global burden of chronic kidney disease.
083
Reposted by Hans-Joachim Anders
NDT @ndt-era.bsky.social · 25/04/2025
Plasma Trimethylamine N-oxide Concentration and All-Cause Mortality in Kidney Transplant Recipients doi.org/10.1093/ndt/...
021
Reposted by Hans-Joachim Anders
NDT @ndt-era.bsky.social · 22/04/2025
Active glomerular inflammation versus chronicity and fibrosis: the role of targeted therapies in IgA nephropathy doi.org/10.1093/ndt/... 📸 Active glomerular inflammation versus chronic fibrotic phenotype in IgAN and potential therapeutic strategies
051
Reposted by Hans-Joachim Anders
NDT @ndt-era.bsky.social · 18/04/2025
Extrarenal manifestations in inherited kidney diseases doi.org/10.1093/ndt/...
032